TL1A, also known as TNFSF15, is a tumor necrosis factor (TNF) family member cytokine predominantly expressed by monocytes, macrophages, dendritic cells (DCs), synovial fibroblasts, and endothelial cells. Its cognate cell surface receptor, DR3 (TNFRSF25), is primarily expressed on T cells, where TL1A signaling co-stimulates T-cell activation and drives pro-inflammatory cytokine production. Dysregulation of the TL1A/DR3 pathway is strongly linked to human inflammatory bowel disease (IBD), Crohn's disease, and various autoimmune pathologies, making it a high-value target for therapeutic antibody screening and biomarker validation.

Product Features & Specifications

• Expression System: Engineered and expressed in an optimized E. coli bacterial system.
• Construct Design: Features a DNA sequence encoding human TL1A (Gln58-Leu251) fused with an N-terminal Polyhistidine (His) tag and an AviTag™ peptide sequence.
• Precision Biotinylation: Enzymatically biotinylated at the unique AviTag™ site, ensuring uniform molecular orientation and maximum ligand binding capacity.
• Native Conformation: Size-exclusion chromatography (SEC) data confirms that the purified recombinant protein elutes as a fully functional homogenous trimer.
• High Purity: Verified at >90% purity by Coomassie blue staining on SDS-PAGE under reducing conditions.

Validated Assay Applications

This biotinylated human TL1A protein is specifically optimized for high-sensitivity binding assays, surface plasmon resonance (SPR), bio-layer interferometry (BLI), AlphaLISA, and ELISA-based high-throughput screening of neutralizing anti-TL1A antibodies.

Catalog Number: TL1A-B-301 | This product is intended for research use only.